Targeted treatments for multiple myeloma: specific role of carfilzomib

Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugumar, Dhivya, Keller, Jesse, Vij, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325627/
https://www.ncbi.nlm.nih.gov/pubmed/25691814
http://dx.doi.org/10.2147/PGPM.S39085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325627/
https://www.ncbi.nlm.nih.gov/pubmed/25691814
http://dx.doi.org/10.2147/PGPM.S39085

Ejemplares similares